[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Aalborg University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":583},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,50,75,103,123,147,174,194,211,250,278,303,321,336,360,377,408,434,454,474,492,511,528,546,566],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":22,"targetDuration":4,"studyType":25,"phases":26,"briefSummary":28,"conditions":29,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100640541","network-effects-of-left-m1-rtms-a-tms-eeg-study-100640541",false,"NCT07580989","Network Effects of Left M1 rTMS: A TMS-EEG Study","Effects of Left Primary Motor Cortex rTMS on Cortical Connectivity Assessed With TMS-EEG Across Left M1, Right M1, Premotor, and Occipital Cortices","CORTEX-4","Inclusion Criteria:\n\n* Healthy men and women\n* Speak and understand English\n\nExclusion Criteria:\n\n* Drug addiction defined as the use of cannabis, opioids or other drugs\n* Previous neurologic, musculoskeletal or mental illnesses\n* Lack of ability to cooperate\n* History of chronic pain or current acute pain\n* Contraindications to rTMS application (history of epilepsy, metal in the head or jaw etc.).\n* Failure to pass the \"TASS questionnaire\" (TASS = Transcranial Magnetic Stimulation Adult Safety Screen)",true,"ALL","18 Years","60 Years",{"count":23,"type":24},20,"ESTIMATED","INTERVENTIONAL",[27],"NA","This study investigates the modification of connectivity patterns in response to one session of active repetitive transcranial magnetic stimulation (rTMS) applied to the primary motor cortex. Transcranial magnetic stimulation (TMS) will be applied to elicit electroencephalography (EEG) responses in healthy volunteers. TMS-evoked potentials (TEPs) will be recorded before and after the rTMS session and will serve as a reflection of cortical connectivity to TMS. Four cortical targets will be stimulated for TMS-EEG assessment: left primary motor cortex, right primary motor cortex, left premotor cortex, and right occipital cortex.",[30],"Cortical Plasticity",[32,33,34,35,36],"Motor cortex","rTMS","TMS-EEG","Visual cortex","Premotor cortex","RECRUITING","2026-05-12",{"date":40,"type":41},"2026-05-14","ACTUAL",{"date":43,"type":41},"2026-05-01",{"date":45,"type":24},"2027-12-31",{"name":47,"class":48},"Aalborg University","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":25,"phases":61,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":49},"100613401","mechanistic-study-of-personalized-rtms-in-chronic-pain-100613401","NCT07266103","Mechanistic Study of Personalized rTMS in Chronic Pain","Building on Previous Evidence: A Mechanistic Clinical Trial of Personalized rTMS for Chronic Pain","PRECISE-Pain","Inclusion Criteria:\n\n* Presence of chronic pain (present most of the days for more than 3 months).\n* Pain with a mean pain intensity between 3-9 on a 0-10 pain scale (where 0 means no pain and 10 means the worst pain imaginable).\n* Speak and understand English or Danish\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Current uncontrolled major depression as the main diagnosis\n* Current history of substance abuse\n* Lack of ability to cooperate, to fully understand the protocol or any difficulty in filling out questionnaires (e.g., due to language or cognitive problems)\n* Formal contraindications to TMS application (presence of epilepsy, cranial implanted ferromagnetic devices, e.g., intracranial neurostimulator or cochlear implants, tattoos with metal ink on the face or permanent make up with metal in the face )\n* Unable to answer the \"Transcranial Magnetic Stimulation Adult Safety Screen\" screening questionnaire.\n* Participation in other research protocols within 1 month before the inclusion.","80 Years",{"count":60,"type":24},90,[27],"Previous research has demonstrated that repetitive magnetic brain stimulation can be an effective adjunctive treatment for several conditions, including chronic pain. However, current stimulation protocols are typically standardized and do not account for individual variability in brain function. This uniform, one-size-fits-all approach results in only about 40% of patients experiencing meaningful clinical benefit, while the remainder show little to no improvement. To address this limitation, the present study will investigate how magnetic stimulation can be tailored to individuals with chronic pain. By analyzing each participant's brain signals prior to treatment, we aim to personalize stimulation parameters to better match individual neural characteristics and potentially enhance therapeutic outcomes. The design of this study builds directly on the findings of a previous clinical trial.",[64],"Chronic Pain",[66,34,33],"pain","2026-05-06",{"date":69,"type":41},"2026-05-07",{"date":71,"type":41},"2026-03-01",{"date":73,"type":24},"2028-05-31",{"name":47,"class":48},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":25,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":49},"100636086","the-impact-of-back-supporting-exoskeletons-for-manual-order-picking-in-danish-warehouses---the-relax-project-100636086","NCT07561112","The Impact of Back-supporting Exoskeletons for Manual Order Picking in Danish Warehouses - The RELAX Project","The Impact of Back-supporting Exoskeletons for Manual Order Picking in Danish Warehouses - The RELAX Project - Protocol for an 18-month In-field Controlled Intervention Study","RELAX","Inclusion Criteria:\n\n* age 18-65 years at enrolment\n* full-time employment in the current work department\n* no major pain or injuries affecting daily work tasks\n\nExclusion Criteria:\n\n* anthropometric characteristics preventing adequate fit of the exoskeleton\n* part-time employment\n* pregnancy or anticipated prolonged absence from work during the study period (standard vacation not included)\n\nIf a participating worker from either the intervention or control group transfers to another department within the company during the intervention period for reasons unrelated to the intervention, the participant will be excluded from the study. Such cases will be classified as dropouts and the corresponding data will be reported as lost to follow-up.","65 Years",{"count":60,"type":24},[27],"This study investigates the long-term effects of implementing a passive back-support exoskeleton during manual order-picking work in a real-world warehouse environment. Work-related musculoskeletal disorders, particularly low back pain, are common among logistics workers due to frequent lifting, repetitive movements, and awkward postures. Although laboratory studies suggest that occupational exoskeletons can reduce biomechanical load, evidence from long-term, real-world workplace implementations remains limited.\n\nThe RELAX project is an 18-month controlled in-field intervention study conducted in two departments of a Danish warehouse. Approximately 90 full-time warehouse workers will participate. Workers in the intervention department will use a passive back-support exoskeleton during manual order-picking tasks, while workers in the control department will continue their work as usual.\n\nThe primary outcomes include sickness absence, employee turnover, perceived work intensity, and musculoskeletal discomfort. Secondary outcomes include productivity, user acceptance of the exoskeleton, and cost-effectiveness of the intervention. Outcomes will be assessed through company records, repeated questionnaires, and focus-group interviews over the 18-month period.\n\nBy combining longitudinal quantitative outcomes with qualitative process evaluation, the study aims to determine whether long-term use of a passive back-support exoskeleton can improve worker well-being and reduce work-related musculoskeletal burden without negatively affecting productivity. The results may inform workplace policies and future implementation of occupational exoskeletons in physically demanding industries.",[88],"Work-Related Musculoskeletal Disorders",[90,91,92,93,94,95],"Occupational Exoskeletons","Musculoskeletal Disorders","Manual Materials Handling","Ergonomics","Assistive Technology","Warehouse","NOT_YET_RECRUITING",{"date":69,"type":41},{"date":99,"type":24},"2026-08-01",{"date":101,"type":24},"2029-10-31",{"name":47,"class":48},{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":110,"targetDuration":4,"studyType":25,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":120,"leadSponsor":122,"locationsCount":49},"100608570","the-role-of-janus-kinase-jak-and-voltage-gated-sodium-channels-nav-on-pain-and-itch-100608570","NCT07203274","The Role of Janus Kinase (JAK) and Voltage-gated Sodium Channels (Nav) on Pain and Itch","The Role of Janus Kinase (JAK) and Voltage-gated Sodium Channels (Nav) on Pain and Itch Sensitivity in Healthy Volunteers","Inclusion Criteria:\n\n* Healthy men and women\n\n  * 18-60 years\n  * Speak and understand English\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n\n  * Drug addiction defined as any use of cannabis, opioids, or other drugs that may cause addiction.\n  * Previous or current history of neurological, dermatological (e.g., AD, psoriasis, etc.), immunological, musculoskeletal, cardiac disorder or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.)\n  * Moles, wounds, scars, or tattoos in the area to be treated or tested\n  * Current use of medications that may affect the trial such as antihistamines and painkillers\n  * use of antihistamines should be discontinued 72 hours before the experiment and all topical agents and emollients should be discontinued 24 hours before the experiment).\n  * Use of systemic and topical corticosteroids\n  * Previous traumatic experience of an electrical accident\n  * Application of moisturizing lotion of the volar site of the forearms (24 hours before study start)\n  * Skin diseases\n  * Consumption of alcohol or painkillers 24 hours before the study days and between these\n  * Acute or chronic pain and itch\n  * Known allergy\u002Fintolerance to lidocaine\u002Fphenytoin\u002Fmepyramine\n  * Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical studies)\n  * Lack of ability to cooperate",{"count":111,"type":24},30,[27],"It is well known that itch and pain have many communalities in terms of pathways and molecules involved. Therefore, it is very important to investi-gate different substances that work against both pain and itching. The substances delgocitinib and lidocaine have both been shown to relieve various types of pain. We therefore assume that these creams will be also able to relieve itching. The purpose of this trial experiment is therefore to investigate the effect of delgocitinib, lidocaine and their combination on experimentally induced itching.",[115],"Itchiness","2026-04-20",{"date":118,"type":41},"2026-04-23",{"date":43,"type":24},{"date":121,"type":24},"2026-12-31",{"name":47,"class":48},{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":25,"phases":133,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":49},"100575612","early-implementation-of-plyometric-exercises-in-the-rehabilitation-of-individuals-suffering-from-lower-extremity-tendinopathies-100575612","NCT06774547","Early Implementation of Plyometric Exercises in the Rehabilitation of Individuals Suffering From Lower-Extremity Tendinopathies","The Efficacy of Early Implementation of Plyometric Exercises in the Rehabilitation of Individuals Suffering From Lower-Extremity Tendinopathies: A Randomised Clinical Trial","Inclusion Criteria:\n\n1. participants are required to have performed either recreational running or participated in sports that include running or jumping activities (e.g., football, basketball, handball, volleyball) at least once per week for at least three months immediately prior to pain onset\n2. have had symptoms for at least three months\n3. have pain\u002Fsoreness with palpation of the tendon\u002Ffascia\n4. mean pain during the past week of at least 2 on a 0 to 10 Numerical Rating Scale\n5. pain during a pain provocation test (patellar tendinopathy: five single-legged decline squats, Achilles tendinopathy and plantar fasciopathy: ten single-legged heel raises)\n\nExclusion Criteria:\n\n1. previous lower-extremity surgery\n2. other lower-extremity musculoskeletal conditions that have required treatment by a healthcare professional during the past three months\n3. pregnancy\n4. diabetes\n5. history of inflammatory systemic diseases (e.g., rheumatoid arthritis or spondylarthritis)\n6. having received an injection with corticosteroid within the past six months.","50 Years",{"count":132,"type":24},120,[27],"This clinical trial aims to compare the effectiveness of an early plyometric exercise approach with traditional heavy, slow resistance training in treating tendinopathies of the Achilles tendon, patellar tendon, and plantar fascia. These conditions, commonly seen in general and rheumatology practices, cause pain, reduced function, and stiffness, often leading to prolonged recovery and incomplete return to full physical activity. The study hypothesizes that introducing plyometric exercises early in rehabilitation will improve jump function after 12 weeks and reduce re-injury rates within 52 weeks compared to traditional methods.\n\nThe study is a randomized clinical trial including 120 participants aged 18-50 with tendinopathy in one of the targeted areas. Participants must regularly engage in running or jumping sports, have symptoms for at least three months, and meet other inclusion criteria. Exclusion criteria include recent surgery or specific medical conditions. Both groups will perform exercises three times weekly for 12 weeks, tailored to their tendinopathy. The intervention group will add progressive plyometric exercises to the standard strength training performed by the control group. Plyometric training will consist of three levels, with patients self-assessing readiness to progress.\n\nThe primary outcome is the change in the plyometric quotient, a measure of functional ability, based on a jump test using a force platform at 0 and 12 weeks. Secondary outcomes include dynamic strength, jump height, patient-reported symptoms (via questionnaires), return to sport, training compliance, adverse events, pain thresholds, re-injury rates, and psychological readiness for sports. Assessments will occur at baseline, 12 weeks, and 52 weeks.",[136,137,138],"Achilles Tendinopathy","Patellar Tendinopathy","Plantar Fasciopathy","2026-03-02",{"date":141,"type":41},"2026-03-04",{"date":143,"type":41},"2025-09-18",{"date":145,"type":24},"2028-01",{"name":47,"class":48},{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":25,"phases":156,"briefSummary":157,"conditions":158,"keywords":162,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":4},"100625694","sleep-hygiene-education-to-improve-sleep-in-chronic-migraine-and-back-pain-100625694","NCT07425964","Sleep Hygiene Education to Improve Sleep in Chronic Migraine and Back Pain","Kan Uddannelse i søvnhygiejne Forbedre søvnkvalitet for Patienter Med Kroniske Smerter?","Inclusion Criteria:\n\n* Chronic back pain (average pain VAS ≥ 3) AND\u002FOR Migraine (migraine or tension headaches ≥15 days per month with ≥8 days being migraine)\n* Lasting ≥3 months\n* Adults ≥18 years old\n* Read, speak, and understand Danish\n* Willing to implement sleep hygiene for four weeks\n* Digital competencies (sufficient to answer questionnaires online)\n\nExclusion Criteria:\n\n* Pregnancy\n* Drug addiction, defined as the use of cannabis, opioids, or other drugs\n* Malignant comorbidity (e.g., cancer)\n* Neurological conditions affecting cognition (e.g., multiple sclerosis, epilepsy, dementia, previous stroke\u002Ftransient cerebral ischemia)\n* Intake of acute headache medication on ≥15 days\u002Fmonth for simple analgesics\u002FNSAIDs or ≥10 days\u002Fmonth for triptans, ergotamine, opioids, or combinations thereof over 3 months.\n* Use of unstable sleep-modulating pharmacological treatment (e.g., melatonin, tricyclic antidepressants)\n* Diagnosed sleep disorder (e.g., insomnia, narcolepsy, sleep apnoea)\n* Night-shift work\n* Initiation of any new therapy during the study period\n* The subject is assessed as unable to engage in the necessary cooperation required by the study",{"count":155,"type":24},100,[27],"The goal of this clinical trial is to learn whether sleep hygiene education can improve sleep quality and reduce pain in adults with migraine and\u002For chronic lower back pain. Poor sleep is common in people with chronic pain and may worsen symptoms. Improving sleep may help break this cycle.\n\nThe main questions this study aims to answer are:\n\n1. Does a four-week sleep hygiene education program improve sleep quality?\n2. Does improved sleep lead to reduced pain intensity and changes in pain sensitivity?\n\nThis study does not include a comparison group. Each participant serves as their own comparison by completing the same tests before and after the sleep hygiene program.\n\nParticipants will:\n\n* Attend two study visits lasting 30-60 minutes, one at the beginning and one after four weeks\n* Complete questionnaires about sleep, pain, mood, and quality of life at both visits\n* Undergo pain sensitivity testing using light pinprick stimulations on the forearm\n* Receive individual sleep hygiene education and written materials to use at home for four weeks\n* Complete a short weekly online check-in about sleep habits and pain\n* Complete a three-month follow-up questionnaire about sleep habits, sleep quality, and pain",[159,160,64,161],"Migraine Disorder","Low Back Pain","Sleep Disorder (Disorder)",[163,164,165],"Sleep Quality","Sleep Hygiene","Pain Sensitivity","2026-02-16",{"date":168,"type":41},"2026-02-23",{"date":170,"type":24},"2026-02",{"date":172,"type":24},"2028-12",{"name":47,"class":48},{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":181,"targetDuration":4,"studyType":25,"phases":182,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":49},"100623379","off-set-analgesia-induced-by-cold-temperature-100623379","NCT07395869","Off-set Analgesia Induced by Cold Temperature","Pain and Itch Neuromodulation: Effects of Offset Analgesia, Placebo, and Nocebo and Topographical Distribution of Itch and Pain Receptors","Inclusion Criteria:\n\n* Healthy men and women\n* 18-60 years\n* Speak and understand English\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Drug addiction defined as any use of cannabis, opioids, or other drugs\n* Previous or current history of neurological, immunological, musculoskeletal, cardiac disorder or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.)\n* Moles, wounds, scars, or tattoos in the area to be treated or tested\n* Current use of medications that may affect the trial such as antihistamines and pain killers\n* Skin diseases\n* Consumption of alcohol or painkillers 24 hours before the study days and between these\n* Acute or chronic pain and itch\n* Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical studies)\n* Contraindications to capsaicin, including intolerance to chili or burns or wounds at the application site (sub-project 4 only)\n* The subject is assessed as unable to engage in the necessary cooperation required by the study",{"count":111,"type":24},[27],"In this study, it will be investigated if the phenomenon of offset analgesia, usually associated with painful heat stimulation, could also be induced using cold painful temperatures.",[185],"Pain","2026-02-09",{"date":188,"type":41},"2026-02-11",{"date":190,"type":24},"2026-02-15",{"date":192,"type":24},"2028-12-31",{"name":47,"class":48},{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":201,"targetDuration":4,"studyType":25,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":208,"leadSponsor":210,"locationsCount":49},"100623380","a-new-model-to-induce-itch-and-inflammation-100623380","NCT07395882","A New Model to Induce Itch and Inflammation","Investigating the Neurophysiology of Itch","Inclusion Criteria:\n\n* Healthy men and women\n* 18-60 years\n* Speak and understand English\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Drug addiction defined as any use of cannabis, opioids, or other addictive drugs\n* Previous or current history of neurological (e.g., neuropathy), immunological (e.g., asthma, immune deficiencies, arthritis), musculoskeletal (e.g., muscular pain in the upper extremities), cardiac disorder (e.g., stroke), or psychiatric diagnoses (e.g., depression, bipolar disorders, acute and chronic psychosis) that may affect the results\n* Current use of medications that may affect the trial, such as antihistamines, antipsychotics, painkillers, and systemic or topical steroids\n* Skin diseases (e.g., atopic dermatitis, pruritus nodularis, eczema, psoriasis)\n* Moles, scars, or tattoos in the area to be treated or tested (forearm\u002Fhand).\n* Consumption of alcohol or painkillers 24 hours before the study days and between these\n* Acute or chronic pain\n* Unable to answer the \"Transcranial Magnetic Stimulation Adult Safety Screen\" (subprojects 2-4)\n* Contraindications to transcranial magnetic stimulation (TMS) application (history of epilepsy, metal implants in head or jaw, etc.) (subprojects 2-4)\n* Presence of implanted hearing aids or metal implants on the face, including permanent makeup or tattoos (subprojects 2-4)\n* Contraindications to capsaicin, including intolerance to chili or burns or wounds at the application sites (subprojects 2, 3, and 4)\n* Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)\n* The subject is assessed as unable to engage in the necessary cooperation required by the study",{"count":5,"type":24},[27],"This project aims to create a reliable, long-lasting itch model by synergistically combining thermal pre-conditioning with the application of histamine or cowhage.",[205],"Itching",{"date":188,"type":41},{"date":190,"type":24},{"date":209,"type":24},"2029-12-31",{"name":47,"class":48},{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":25,"phases":220,"briefSummary":221,"conditions":222,"keywords":226,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":249},"100621651","effects-of-lp-ldl-on-lipid-metabolism-glycemic-control-inflammatory-markers-and-cognitive-function-in-individuals-with-prediabetes-and-diabetes-mellitus-100621651","NCT07373392","Effects of LP-LDL® on Lipid Metabolism, Glycemic Control, Inflammatory Markers, and Cognitive Function in Individuals With Prediabetes and Diabetes Mellitus","Effects of LP-LDL® on Lipid Metabolism, Glycemic Control, Inflammatory Markers, and Cognitive Function in Individuals With Prediabetes and Diabetes Mellitus (Type 1 and Type 2)","Inclusion Criteria:\n\n* Adults ≥ 18 years\n* Prediabetes (FPG 100-125 mg\u002FdL or HbA1c 42-47 mmol\u002Fmol), or Type 1 or Type 2 diabetes\n* Elevated cholesterol or triglycerides (TC ≥200 mg\u002FdL, LDL 130-189 mg\u002FdL, or TG \\>150 mg\u002FdL)\n* Either no lipid-lowering medication or stable dose for ≥4 weeks\n* Able to swallow capsules and understand Danish\n* Willing to maintain lifestyle habits and provide stool and blood samples\n\nExclusion Criteria:\n\n* Antibiotic use in the past 3 months\n* Severe dyslipidemia (\\>500 mg\u002FdL triglycerides)\n* Significant liver, kidney, thyroid disease\n* Pregnancy or breastfeeding\n* GI surgery or chronic GI disease (IBD, IBS, Crohn's disease)\n* Long-term medications influencing lipid\u002Fglucose metabolism (except approved antidiabetic medications)\n* Participation in another trial within 3 months\n* Capsule intake \\\u003C80%",{"count":219,"type":24},210,[27],"This randomized, double-blind, placebo-controlled clinical trial investigates the effects of the probiotic LP-LDL® (Lactobacillus plantarum ECGC 13110402) on lipid metabolism, glycemic control, inflammatory biomarkers, and cognitive function in adults with prediabetes, type 1 diabetes, or type 2 diabetes who also exhibit elevated cholesterol or triglyceride levels.\n\nA total of 210 participants will be enrolled across three parallel sub-studies:\n\n* Type 1 diabetes (n = 76)\n* Type 2 diabetes (n = 54)\n* Prediabetes (n = 80)\n\nParticipants will be randomized 1:1 to receive LP-LDL® or matching placebo once daily for 12 weeks, followed by a 4-week washout period. Study assessments include fasting blood tests (lipids, glucose, HbA1c, liver enzymes, inflammatory markers), cognitive testing (ACE-III), blood pressure, anthropometry, and stool measurements (microbiome, bile acids, fecal fat).\n\nExploratory analyses include bile acid metabolism, microbiome profiling (16S rRNA), and gene expression of cholesterol transporters ABCG5\u002FABCG8.\n\nThe study aims to determine whether LP-LDL® can improve cardiometabolic profiles and cognitive outcomes in these populations, and to clarify the mechanistic pathways underlying metabolic dysfunction, inflammation, and gut-brain communication.",[223,224,225],"Diabete Type 1","Diabete Type 2","Prediabetes",[225,227,228,229,230,231,232,233,234,235,236,237,238,239,240],"Type 1 Diabetes","Type 2 Diabetes","Dyslipidemia","Hypercholesterolemia","Metabolic dysfunction","Insulin resistance","Probiotics","LP-LDL","Lactobacillus plantarum","Lactobacillus plantarum ECGC 13110402","Dietary supplement","Microbiome modulation","LDL cholesterol","Cardiometabolic health","2026-01-27",{"date":243,"type":41},"2026-01-29",{"date":245,"type":24},"2026-01-25",{"date":247,"type":24},"2028-09-01",{"name":47,"class":48},2,{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":261,"phases":4,"briefSummary":262,"conditions":263,"keywords":266,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":249},"100584117","remote-monitoring-of-cardiac-mechanics-in-heart-failure-patients-100584117","NCT06885164","Remote Monitoring of Cardiac Mechanics in Heart Failure Patients","Seismocardiographic Monitoring in Heart Failure","SeismicHeart","Inclusion Criteria:\n\n* NYHA Class II or higher\n* 18-90 years old\n\nExclusion Criteria:\n\n* Pregnancy\n* Drug addiction defined as the use of cannabis, opioids, or other drugs\n* Mechanical heart valves\n* In dialysis\n* Not possible to obtain clinical echocardiography of sufficient quality\n* Lack of ability to coorperate","90 Years",{"count":260,"type":24},200,"OBSERVATIONAL","Heart failure is a severe heart disease, where the heart's ability to pump blood is unsatisfactory. The consequence is a high risk of hospitalization and death. Heart failure is treated with medicine which relieves symptoms and slows down the disease progression. This medical treatment needs routine adjustment, but in many cases, this adjustment is not done timely, which results in life treating conditions where the patients need acute hospitalization. Remote health monitoring of HF patients has the potential to ensure timely adjustment. However, only sensors placed inside the blood vessels of the lung, have been shown effective. The disadvantage is that the placement of the sensor requires surgery. This makes the method costly and poses a risk for the patient. The aim of the current project is to develop a small intelligent patch, which can measure the heart's function from the outside of the body. The method will be low-cost, simple to use and will not pose a risk to the patient.",[264,265],"Heart Failure","Heart Failure - NYHA II - IV",[267,268,269],"heart failure","remote monitoring","cardiac mechanics","2026-01-15",{"date":272,"type":41},"2026-01-16",{"date":274,"type":41},"2025-06-11",{"date":276,"type":24},"2027-01-01",{"name":47,"class":48},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":18,"sex":19,"minAge":285,"maxAge":21,"enrollmentInfo":286,"targetDuration":4,"studyType":25,"phases":288,"briefSummary":289,"conditions":290,"keywords":292,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":49},"100617933","tonic-pain-and-transauricular-vagal-nerve-stimulation-100617933","NCT07325058","Tonic Pain and Transauricular Vagal Nerve Stimulation","Exploration of the Effect, and Their Duration, of Different Frequency Transcutaneous Auricular Vagal Nerve Stimulation on Sensory Perception.","Inclusion Criteria:\n\n* Healthy\n* Speak and understand English\n* 18-60 years old.\n\nExclusion Criteria:\n\n* Pregnant and\u002For breastfeeding\n* Regular use of cannabis, opioids or other drugs\n* Current or previous neurologic, musculoskeletal, mental, or other illnesses (e.g., brain or spinal cord injuries, degenerative neurological disorders, major depression, cardiovascular disease, chronic lung disease, etc.)\n* Current regular (once or more a week) use of analgesic medication or other medication which may affect the trial (including paracetamol and NSAIDs)\n* Recent history of acute pain particularly in the lower limbs\n* Abnormally disrupted sleep in 24 hours preceding experiment\n* Contraindications to electric stimulation application (history of epilepsy, metal implants in head or jaw, etc.)\n* Lack of ability to cooperate\n* Contraindications for capsaicin including an intolerance chili consumption and burns or wounds to the application site.","16 Years",{"count":287,"type":24},36,[27],"This study aims to explore the effect of burst-taVNS (electric stimulation of the concha cymba) on tonic (capsaicin-induced skin pain) and acute (pressure pain sensitivity) experimental pain and cardioception. Primary outcomes include pain intensity. Secondary outcomes include sensory thresholds, resting heart rate (EKG), pupillary measurements and conditioned pain modulation.",[291],"Experimental Pain in Healthy Human Subjects",[293,294],"cross-over","taVNS","2025-12-31",{"date":297,"type":41},"2026-01-08",{"date":299,"type":41},"2025-12-18",{"date":301,"type":24},"2026-04",{"name":47,"class":48},{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":179,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":309,"targetDuration":4,"studyType":25,"phases":310,"briefSummary":311,"conditions":312,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":320,"locationsCount":49},"100612554","mechanisms-underlying-the-nocibo-effect-of-contagious-itch-in-both-histaminergic-and-nonhistaminergic-itch-100612554","NCT07255092","Mechanisms Underlying the Nocibo Effect of Contagious Itch. in Both Histaminergic and Nonhistaminergic Itch","Inclusion Criteria:\n\n* 18-60 years\n* Speak and understand English\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Drug addiction defined as any use of cannabis, opioids, or other drugs\n* Previous or current history of neurological, immunological, musculoskeletal, cardiac disorder or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.)\n* Moles, wounds, scars, or tattoos in the area to be treated or tested\n* Current use of medications that may affect the trial such as antihistamines and pain killers\n* Skin diseases\n* Consumption of alcohol or painkillers 24 hours before the study days and between these\n* Acute or chronic pain and itch\n* Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical studies)\n* Contraindications to capsaicin, including intolerance to chili or burns or wounds at the application site\n* The subject is assessed as unable to engage in the necessary cooperation required by the study",{"count":111,"type":24},[27],"The study consists of one experimental session of approximately 1½ hours. The participant will fill in a series of questionnaires about how you perceive itch and pain, and about some traits of your personality, such as depression, anxiety and stress. Afterwards, three areas will be selected on each forearm of the subjects.\n\nTwo areas will be treated with histamine, two with cowhage, and two with vehicle. One application of each substance will be conducted including the contagious itch component. During the 10 minutes of the application of the pruritogens, itch and pain will be continuously monitored using a VAS scale.",[313],"ITCH","2025-11-27",{"date":316,"type":41},"2025-12-04",{"date":318,"type":24},"2025-12-01",{"date":192,"type":24},{"name":47,"class":48},{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":179,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":327,"targetDuration":4,"studyType":25,"phases":328,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":331,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":335,"locationsCount":49},"100611985","mechanisms-underlying-the-placebo-effect-in-both-histaminergic-and-non-histaminergic-itch-100611985","NCT07247695","Mechanisms Underlying the Placebo Effect in Both Histaminergic and Non-histaminergic Itch","Inclusion Criteria:\n\n* Healthy men and women\n* 18-60 years\n* Speak and understand English\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Drug addiction defined as any use of cannabis, opioids, or other drugs\n* Previous or current history of neurological, immunological, musculoskeletal, cardiac disorder or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.)\n* Moles, wounds, scars, or tattoos in the area to be treated or tested\n* Current use of medications that may affect the trial such as antihistamines and pain killers\n* Skin diseases\n* Consumption of alcohol or painkillers 24 hours before the study days and between these\n* Acute or chronic pain and itch\n* Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical studies)\n* Contraindications to capsaicin, including intolerance to chili or burns or wounds at the application site\n* The subject is assessed as unable to engage in the necessary cooperation required by the study",{"count":111,"type":24},[27],"The study consists of one experimental session of approximately 1½ hours. The participant will fill in a series of questionnaires about how you perceive itch and pain, and about some traits of your personality, such as depression, anxiety and stress. Afterwards, two areas will be selected on each forearm of the subjects. The four areas will be treated with the same vehicle cream for 20 minutes, in order to test the placebo effect. At the end of the cream application, two areas will be randomly treated with histamine while cowhage will be applied on the other two areas. During the 10 minutes of the application of the pruritogens, itch and pain will be continuously monitored using a Visual Analog Scale.",[313],{"date":316,"type":41},{"date":333,"type":41},"2025-11-03",{"date":192,"type":24},{"name":47,"class":48},{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":58,"enrollmentInfo":343,"targetDuration":4,"studyType":25,"phases":344,"briefSummary":345,"conditions":346,"keywords":347,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":49},"100611974","personalized-treatment-by-rtms-in-chronic-pain---study2-100611974","NCT07247552","Personalized Treatment by rTMS in Chronic Pain - Study2","Personalized Pain Treatment by Transcranial Magnetic Stimulation in Patients With Chronic Pain: A Prospective Interventional Study With Embedded Predictive Biomarker Evaluation","PersoNINpain",{"count":60,"type":24},[27],"Previous research has shown the effectiveness of magnetic stimulation of the brain as a supplemental treatment for various conditions, such as depression and chronic pain. However, the application of magnetic stimulation has been standardized across patients without considering individual differences. This one-size-fits-all approach results in only half of the patients benefiting from the treatment, with the other half seeing no improvement in their symptoms. Therefore, a study on individuals with chronic pain will be performed to explore how magnetic stimulation treatments can be tailored to each person. This will involve analysing brain signal measurements before the start of the therapy and adjusting\u002Fpersonalizing the magnetic stimulations to each individual person.",[64],[185,348,349,350,64,351,352],"Neurologic Manifestations","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Transcranial Magnetic Stimulation","Neuromodulation","2025-11-24",{"date":318,"type":41},{"date":356,"type":41},"2025-04-01",{"date":358,"type":24},"2026-06",{"name":47,"class":48},{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":179,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":365,"targetDuration":4,"studyType":25,"phases":366,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":376,"locationsCount":49},"100602397","topographical-distribution-of-itch-and-pain-receptors-100602397","NCT07122973","Topographical Distribution of Itch and Pain Receptors",{"count":111,"type":24},[27],"The experiment consists of three experimental sessions conducted on three consecutive days.\n\nIn all experimental sessions, the participant will fill in a series of questionnaires about how you perceive itch and pain, and about some traits of your personality, such as depression, anxiety and stress.\n\nIn the first session, we will mark six test areas in your face (three on each side on jaw, cheek, and temple, respectively). Thent a series of measure-ments in each test area will be conducted:measurement of the blood flow in the skin and sensitivity tests to pressure, pinprick and stroke with a brush.\n\nIn the second session, histamine will be applied in one side of the face. On the other side, cowhage spicules will be applied. After 10 minutes, all the tests will be conducted again.\n\nThe third session will be identical to the second. However, instead of histamine and spicules, patches containing capsaicin will be applied. In the other side, we will apply patches with placebo (i.e., a non-active patch). After 20 minutes all the tests will be conducted again.",[185,369],"Itch","2025-09-30",{"date":372,"type":41},"2025-10-01",{"date":374,"type":41},"2025-09-17",{"date":192,"type":24},{"name":47,"class":48},{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":381,"acronym":382,"eligibilityCriteria":383,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":384,"enrollmentInfo":385,"targetDuration":4,"studyType":261,"phases":4,"briefSummary":387,"conditions":388,"keywords":391,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":249},"100603263","development-of-computational-models-to-predict-the-short--medium--and-long-term-cartilage-degeneration-and-pain-for-patients-with-early-stage-osteoarthritis-or-anterior-cruciate-ligament-injury-100603263","NCT07134244","Development of Computational Models to Predict the Short-, Medium- and Long-term Cartilage Degeneration and Pain for Patients With Early-stage Osteoarthritis or Anterior Cruciate Ligament Injury","MathKOA",".3.1 ACL reconstruction group (n= 25) Inclusion criteria\n\n* Adults under 70 years\n* ACL injury within the last year and planned for ACL reconstruction at inclusion\n* Informed consent form signed Exclusion criteria (at inclusion)\n* Previous knee surgery before current knee trauma.\n* Severe ischemic or neurological sequelae.\n* BMI above 32.\n* Clinically significant joint disease (inflammatory or degenerative) to other joints than the ACL injured knee (according to the clinician).\n* Unsuitable for MRI (e.g. pacemaker or claustrophobia)\n* Participants not able to fit the MRI knee coil (Thigh circumference larger than 73.5 cm measured 10 cm above the kneecap and a maximum calf circumferences of 61.5 cm).\n* Drug addiction defined as the use of cannabis, opioids or other drugs as reported by the participant\n\nACL no reconstruction group (n= 25) Inclusion criteria\n\n* Adults under 70 years\n* ACL injury within the last year and with no plans for ACL reconstruction at inclusion\n* Informed consent form signed Exclusion criteria (at inclusion)\n* Previous knee surgery before current knee trauma.\n* Severe ischemic or neurological sequelae.\n* BMI above 32.\n* Clinically significant joint disease (inflammatory or degenerative) to other joints than the ACL injured knee (according to the clinician).\n* Unsuitable for MRI (e.g. pacemaker or claustrophobia)\n* Participants not able to fit the MRI knee coil (Thigh circumference larger than 73.5 cm measured 10 cm above the kneecap and a maximum calf circumferences of 61.5 cm).\n* Drug addiction defined as the use of cannabis, opioids or other drugs as reported by the participant\n\nEarly to moderate knee OA stage (n= 25) Inclusion criteria\n\n* Adults under 70 years\n* Diagnosis of knee OA (Kellgren Lawrence (KL) grade 1, 2 and 3 (Kohn et al., 2016). If there is no X-ray that is a maximum of 1 year old, a new one is taken.\n* Stress-related pain in the knee and knee stiffness\n* Informed consent form signed Exclusion criteria (at inclusion)\n* Previous knee surgery\n* Clinically significant joint disease (inflammatory or degenerative) of other joints than the knee at inclusion.\n* Severe ischemic or neurological sequelae in the lower extremities.\n* Clinically significant joint disease (inflammatory or degenerative) to other joints than the knees (according to the clinician).\n* BMI above 32.\n* Unsuitable for MRI (e.g., pacemaker or claustrophobia)\n* Participants not able to fit the MRI knee coil (Thigh circumference larger than 73.5 cm measured 10 cm above the kneecap and a maximum calf circumferences of 61.5 cm).\n* Drug addiction defined as the use of cannabis, opioids or other drugs as reported by the participant\n\nControl groups (3 groups of 10 control participants matched for each of the patient groups, n=30) Inclusion criteria\n\n* Adults under 70 years\n* Informed consent form signed\n* No radiological changes on a knee x-ray (Arendt-Nielsen et al., 2015). Exclusion criteria (at inclusion)\n* Previous knee surgery\n* Self-reported Knee problems (pain, stiffness)\n* Clinically significant joint disease (inflammatory or degenerative) at inclusion.\n* Severe ischemic or neurological sequelae in the lower extremities.\n* BMI above 32.\n* Unsuitable for MRI (e.g., pacemaker or claustrophobia)\n* Participants not able to fit the MRI knee coil (Thigh circumference larger than 34.3-73.5 cm measured 10 cm above the kneecap and a maximum calf circumferences of 61.5 cm).\n* Drug addiction defined as the use of cannabis, opioids, or other drugs as reported by the participant","70 Years",{"count":386,"type":24},105,"Knee osteoarthritis is a complex condition, and selecting effective non-drug treatments like orthoses or exercise is often difficult and imprecise. This study will follow individuals with early-stage knee osteoarthritis or previous anterior cruciate ligament injury to develop computational models that predict cartilage degeneration and pain over time. The models will integrate data from medical imaging, movement analysis, muscle strength testing, pain assessments, questionnaires, and biomarkers to improve personalized treatment planning.",[389,390],"Osteoarthritis, Knee","Anterior Cruciate Ligament Injuries",[392,393,394,395,396,397,398,399],"Knee joint","Cartilage degeneration","Biomechanics","Computational modeling","Pain assessment","Musculoskeletal modeling","Finite element analysis","MRI","2025-08-14",{"date":402,"type":41},"2025-08-21",{"date":404,"type":41},"2024-09-26",{"date":406,"type":24},"2036-09-26",{"name":47,"class":48},{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":18,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":25,"phases":417,"briefSummary":418,"conditions":419,"keywords":421,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":433,"locationsCount":49},"100602751","ultrasound-simulation-or-traditional-ultrasound-training-for-general-practitioners-100602751","NCT07127588","Ultrasound Simulation or Traditional Ultrasound Training for General Practitioners?","Continuing Education of General Practitioners in Clinical Ultrasound - Ultrasound Simulation or Traditional Ultrasound Training?","Inclusion Criteria:\n\n* The participant must be a postgraduate medical doctor specialized in general medicine\u002Ffamily medicine (general practitioner).\n* The participant must have access to an ultrasound device during the study period.\n\nExclusion Criteria:\n\n* General practitioners who have already participated in a basic point-of-care ultrasound education for general practitioners.\n* General practitioners with potential conflicts of interest.\n* Individuals with no signed informed consent to participate.",{"count":416,"type":24},24,[27],"The goal of this study is to compare two different educational methods for training general practitioners (GPs) in point-of-care ultrasound. The main question it aims to answer is:\n\n\\- Does the use of ultrasound phantoms and simulators result in superior post-course ultrasound skills compared to traditional training methods involving healthy volunteers? Researchers will compare a group trained with traditional methods (scanning healthy volunteers) to a group trained using ultrasound phantoms and simulators to see if the different training methods result in different levels of ultrasound proficiency.\n\nParticipants will:\n\n* Be 24 general practitioners randomized into two groups of 12.\n* Receive training in five clinical ultrasound examinations: 1) Aortic abdominal aneurism, 2) gallstones, 3) pleural effusion, 4) hydronephrosis, and 5) free fluid in the abdomen (FAST scan).\n* Begin with e-learning, followed by two in-person teaching seminars.\n* Train at their clinics between course days: first on healthy volunteers, then on indicated patients.\n* Upload scans to an online learning platform and receive feedback from instructors.\n* Be assessed after 90 days using the validated Objective Structured Assessment of Ultrasound Skills (OSAUS) tool, with blinded evaluators.",[420],"Ultrasound Training",[422,423,424,425,426,427],"Point-of-care ultrasound","Clinical ultrasound","Education","General practitioners","Simulation","Randomised controlled trial",{"date":429,"type":41},"2025-08-17",{"date":431,"type":41},"2025-06-26",{"date":316,"type":24},{"name":47,"class":48},{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":440,"eligibilityCriteria":441,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":442,"targetDuration":4,"studyType":25,"phases":443,"briefSummary":444,"conditions":445,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":452,"locationsCount":453},"100554778","role-of-interleukin-13-pathways-on-pain-and-itch-sensitivity-100554778","NCT06503510","Role of Interleukin-13 Pathways on Pain and Itch Sensitivity","The Role of the Interleukin-13 Pathways on Pain and Itch Sensitivity in Patients With Atopic Dermatitis and Healthy Volunteers","IL-13","Inclusion Criteria:\n\n* Healthy men and women\n* 18-60 years\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Drug addiction defined as any use of cannabis, opioids, or other drugs\n* Previous or current history of neurological, dermatological (e.g., AD, psoriasis, etc.), immunological, musculoskeletal, cardiac disorder, or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.)\n* Moles, wounds, scars, or tattoos in the area to be treated or tested\n* Current use of medications that may affect the trial such as antihistamines and pain killers (use of antihistamines should be discontinued 72 hours before the experiment and all topical agents and emollients should be discontinued 24 hours before the experiment).\n* Use of systemic and topical corticosteroids\n* Consumption of alcohol or painkillers 24 hours before the study days and between these\n* Acute or chronic pain\n* Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)\n* Lack of ability to cooperate",{"count":23,"type":24},[27],"Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the proteins interleukins are involved in inflammation and itch in atopic dermatitis. The medicinal product called Lebrikizumab, used for treatment of AD, has shown to block the interleukin called IL-13. The purpose of this experiment is to evaluate the role of IL-13 in itch in both healthy subjects and people with atopic dermatitis.",[369],"2025-05-30",{"date":448,"type":41},"2025-06-04",{"date":450,"type":41},"2025-01-06",{"date":121,"type":24},{"name":47,"class":48},3,{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":461,"targetDuration":4,"studyType":25,"phases":463,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":49},"100580134","efficacy-of-hip-belt-squat-training-on-pain-management-and-physcial-function-in-low-back-pain-patients-100580134","NCT06833346","Efficacy of Hip Belt Squat Training on Pain Management and Physcial Function in Low Back Pain Patients","BASICS: Back-pain Alleviation Via a Specific and Inexpensive Contextual Strength Training Protocol","Inclusion Criteria:\n\n* Men and women with non-specific low back pain for more than twelve weeks, with a VAS score of at least 3, taken as an average of the last week, and ODI\\>20\n\nExclusion Criteria:\n\n* Leg pain greater than back pain\n* Neuromuscular disorders\n* Spinal or lower extremity fractures\n* Infections\n* Cancer\n* Osteoporosis\n* Dementia\n* Current substance abuse\n* Former lumbar surgery\n* Persistent pain syndromes other than back pain\n* Inflammatory rheumatic diseases",{"count":462,"type":24},60,[27],"The purpose of this project is to investigate the efficacy of the hip belt squat exercise in pain management and physical function for people with chronic low back pain.",[160],"2025-03-05",{"date":468,"type":41},"2025-03-07",{"date":470,"type":24},"2025-03-01",{"date":472,"type":24},"2026-08",{"name":47,"class":48},{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":481,"targetDuration":4,"studyType":25,"phases":482,"briefSummary":483,"conditions":484,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":491,"locationsCount":249},"100554779","the-effects-of-performing-a-motor-imagery-task-on-cortical-excitability-during-acute-experimental-muscle-pain-and-acute-itch-100554779","NCT06503523","The Effects of Performing a Motor Imagery Task on Cortical Excitability During Acute Experimental Muscle Pain and Acute Itch","Investigation of the Neurophysiological and Psychological Aspects of Itch","Inclusion Criteria:\n\n* Healthy men and women\n* 18-60 years\n* Speak and understand English\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Drug addiction defined as any use of cannabis, opioids, or other addictive drugs\n* Previous or current history of neurological (e.g. neuropathy), immunological (e.g. asthma, immune deficiencies, arthritis), musculoskeletal (e.g. muscular pain in the upper extremities,), cardiac disorder (e.g., heart stroke), or psychiatric diagnoses (e.g. depression) that may affect the results\n* Current use of medications that may affect the trial, such as antihistamines, antipsychotics, and painkillers, as well as systemic or topical steroids\n* Skin diseases (e.g., atopic dermatitis, pruritus nodularis, eczema, psoriasis)\n* Moles, scars, or tattoos in the area to be treated or tested.\n* Consumption of alcohol or painkillers 24 hours before the study days and between these\n* Acute or chronic pain\n* Unable to pass the \"Transcranial Magnetic Stimulation Adult Safety Screen\" (subproject 1 and 2)\n* Contraindications to transcranial magnetic stimulation (TMS) application (history of epilepsy, metal implants in head or jaw, etc.)\n* Presence of implanted hearing aids or metal implants on the face, including permanent makeup or tattoos\n* Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)\n* Lack of ability to cooperate",{"count":111,"type":24},[27],"The aim of this project is to determine the effects of performing a motor imagery task on cortical excitability during acute experimental muscle pain (induced by hypertonic saline), acute histaminergic itch (induced by histamine), and non-histaminergic itch stimulation (triggered by Cowhage). We hypothesize that motor imagery will counteract the alterations in cortical excitability observed during experimental muscle pain and both itch models.",[369,185],"2024-11-20",{"date":487,"type":41},"2024-11-22",{"date":489,"type":41},"2024-10-01",{"date":121,"type":24},{"name":47,"class":48},{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":499,"targetDuration":4,"studyType":25,"phases":501,"briefSummary":502,"conditions":503,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":506,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":510,"locationsCount":49},"100541337","itch-sensation-induced-by-multiple-applications-of-pruritogens-temporal-summation-100541337","NCT06328543","Itch Sensation Induced by Multiple Applications of Pruritogens (temporal Summation)","Repetitive Applications of Pruritogens and Effects of a Cutaneous-induced Pain Stimulation on Nonhistaminergic Itch Perception","Inclusion Criteria:\n\n* Healthy men and women\n* 18-60 years\n* Speak and understand Englis\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Drug addiction defined as any use of cannabis, opioids, or other addictive drugs\n* Previous or current history of neurological (e.g. neuropathy), immunological (e.g. asthma, immune deficiencies, arthritis), musculoskeletal (e.g. muscular pain in the upper extremities,), cardiac disorder, or mental illnesses that may affect the results\n* Lack of ability to cooperate\n* Current use of medications that may affect the trial such as antihistamines, antipsychotics, and pain killers, as well as systemic or topical steroids\n* Skin diseases (e.g. atopic dermatitis, pruritus nodularis, eczema, psoriasis)\n* Moles, scars, or tattoos in the area to be treated or tested.\n* Consumption of alcohol or painkillers 24 hours before the study days and between these\n* Acute or chronic pain\n* Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)",{"count":500,"type":24},26,[27],"In This experiment, the investigators would like to design a new itch model based on the temporal summation of pruritic stimuli. The hypothesis behind this study (temporal summation) is that two overlapped applications of pruritogens will result in a higher itch sensation compared with a single application.",[504,505],"Histamine","Cowhage",{"date":487,"type":41},{"date":508,"type":41},"2024-11-01",{"date":121,"type":24},{"name":47,"class":48},{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":518,"targetDuration":4,"studyType":25,"phases":519,"briefSummary":520,"conditions":521,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":523,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":527,"locationsCount":49},"100522386","investigation-of-the-effects-of-sleep-fragmentation-on-itch-and-pain-sensitivity-100522386","NCT06081946","Investigation of the Effects of Sleep Fragmentation on Itch and Pain Sensitivity","Investigation of the Effects of Sleep Provocations on Itch and Pain Sensitivity","Inclusion Criteria:\n\n* Healthy men and women\n* 18-60 years\n* Speak and understand English\n* Access to a smartphone during the experimental nights\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Drug addiction defined as any use of cannabis, opioids, or other drugs\n* Previous or current history of neurological, dermatological, immunological musculoskeletal, cardiac disorder or mental illnesses (psychiatric diagnosis) that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia etc.)\n* Moles, wounds, scars, or tattoos in the area to be treated or tested\n* Current use of medications that may affect the trial such as antihistamines and pain killers.\n* Skin diseases\n* Consumption of alcohol or painkillers 24 hours before the study days and between these\n* Acute or chronic pain and itch\n* Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical studies)\n* Lack of ability to cooperate",{"count":111,"type":24},[27],"In This experiment, the investigators would like to test following hypotheses regarding the influence of sleep fragmentation on itch:\n\n* To investigate similarity and differences between itch and pain by comparing the effect of sleep deprivation in them.\n* To evaluate the inflammatory state induced by sleep fragmentation via the analysis of C-reactive protein (CRP) levels from blood samples.\n* To correlate the anxiety and depression scores (evaluated through questionnaires) with itch and pain sensitivity and evaluate how they are affected by sleep fragmentation.",[504,505,522],"Sleep Fragmentation",{"date":487,"type":41},{"date":525,"type":41},"2023-12-15",{"date":121,"type":24},{"name":47,"class":48},{"id":529,"slug":530,"hasResults":12,"nctId":531,"briefTitle":532,"officialTitle":479,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":534,"targetDuration":4,"studyType":25,"phases":536,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":545,"locationsCount":49},"100542251","investigate-the-relationship-between-catastrophizing-and-the-perception-of-itch-intensity-in-healthy-individuals-100542251","NCT06340438","Investigate the Relationship Between Catastrophizing and the Perception of Itch Intensity in Healthy Individuals","Inclusion Criteria:\n\n* Healthy men and women\n* 18-60 years\n* Speak and understand English\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Drug addiction defined as any use of cannabis, opioids, or other addictive drugs\n* Previous or current history of neurological (e.g. neuropathy), immunological (e.g. asthma, immune deficiencies, arthritis), musculoskeletal (e.g. muscular pain in the upper extremities,), cardiac disorder, or mental illnesses that may affect the results\n* Lack of ability to cooperate\n* Current use of medications that may affect the trial such as antihistamines, antipsychotics, and pain killers, as well as systemic or topical steroids\n* Skin diseases (e.g. atopic dermatitis, pruritus nodularis, eczema, psoriasis)\n* Moles, scars, or tattoos in the area to be treated or tested.\n* Consumption of alcohol or painkillers 24 hours before the study days and between these\n* Acute or chronic pain\n* Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)",{"count":535,"type":24},46,[27],"This project aims to investigate the relationship between different dimensions of catastrophizing (rumination, magnification, and helplessness) as well as some specific personality traits related to catastrophizing tendencies like anxiety sensitivity and fear sensitivity in the modulation of itch and pain intensities in an experimental setting.",[504,505],"2024-06-19",{"date":541,"type":41},"2024-06-24",{"date":543,"type":41},"2024-04-27",{"date":121,"type":24},{"name":47,"class":48},{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":19,"minAge":553,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":25,"phases":555,"briefSummary":556,"conditions":557,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":563,"leadSponsor":565,"locationsCount":49},"100551131","feasibility-of-a-home-exercise-program-with-the-addition-of-a-corticosteroid-injection-in-patients-with-lateral-hip-pain-100551131","NCT06456099","Feasibility of a Home Exercise Program With the Addition of a Corticosteroid Injection in Patients With Lateral Hip Pain","Feasibility of a Home Exercise Program With the Addition of a Corticosteroid Injection in Patients With Greater Trochanteric Pain Syndrome in General Practice","Inclusion Criteria:\n\n* 35 years of age\n* Self-reported pain on the outside of the hip for at least 12 weeks with an average intensity of present pain over the last week of at least 4\u002F10 on a numeric rating scale 0-10 (0 being no hip pain and 10 being worst hip pain imaginable)\n* Access to a computer, smartphone or tablet with internet connection\n* Tenderness on palpation of the greater trochanter\n* Reproduction of lateral hip pain with 30 sec single leg stance test\n* Ability to speak and understand Danish (written and oral)\n* In case of bilateral hip pain, the study hip will be the most painful at inclusion\n\nExclusion Criteria:\n\n* Corticosteroid injection in the affected hip or other new treatment by a health professional within the last 3 months\n* History of systemic inflammatory diseases, e.g. rheumatoid arthritis, spondyloarthritis\n* Weekly intake of oral glucocorticoids\n* History of other hip conditions, e.g. clinically significant hip osteoarthritis, hip dysplasia, prior hip surgery\n* History of prior lumbar back surgery\n* Current low back pain or episodes of low back pain within the last 3 months that have caused sick leave and\u002For treatment by a health professional\n* Physical or mental disabilities that make it impossible to understand and\u002For perform exercises and complete questionnaires\n* Current or planned pregnancy or breastfeeding","35 Years",{"count":23,"type":24},[27],"We have developed an exercise protocol that we plan to evaluate in a future randomized controlled trial in combination with a corticosteroid injection. In accordance with the MRC Framework of Complex Interventions, which reccomends stepwise development of interventions and testing of feasibility before applying them to a trial, we aim to evaluate the feasibility of our intervention before initiating further trials.\n\nThe purpose of this non-randomized feasibility study is to test the feasibility and acceptability of this exercise protocol with addition of a corticosteroid injection with no aim of evaluating effects.\n\nAll participants in this study will receive the following interventions:\n\n* An ultrasound-guided corticosteroid injection superficial to the insertion of the gluteus medius and minimus tendons on the greater trochanter of the hip.\n* A home exercise program including 3 exercises, scalable to 3 different difficulty levels.\n* A patient information leaflet containing relevant information on managing lateral hip pain.",[558],"Greater Trochanteric Pain Syndrome","2024-06-07",{"date":561,"type":41},"2024-06-13",{"date":559,"type":41},{"date":564,"type":24},"2024-09-30",{"name":47,"class":48},{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":497,"acronym":4,"eligibilityCriteria":571,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":572,"targetDuration":4,"studyType":25,"phases":573,"briefSummary":574,"conditions":575,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":582,"locationsCount":49},"100541336","itch-sensation-induced-by-simultaneous-application-of-pruritogens-spatial-summation-100541336","NCT06328530","Itch Sensation Induced by Simultaneous Application of Pruritogens (Spatial Summation)","Inclusion Criteria:\n\n* Healthy men and women\n* 18-60 years\n* Speak and understand English\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Drug addiction defined as any use of cannabis, opioids, or other addictive drugs\n* Previous or current history of neurological (e.g. neuropathy), immunological (e.g. asthma, immune deficiencies, arthritis) musculoskeletal (e.g. muscular pain in the upper extremities,), cardiac disorder, or mental illnesses that may affect the results\n* Lack of ability to cooperate\n* Current use of medications that may affect the trial such as antihistamines, antipsychotics, and pain killers, as well as systemic or topical steroids\n* Skin diseases (e.g. atopic dermatitis, pruritus nodularis, eczema, psoriasis)\n* Moles, scars, or tattoos in the area to be treated or tested.\n* Consumption of alcohol or painkillers 24 hours before the study days and between these\n* Acute or chronic pain\n* Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)",{"count":416,"type":24},[27],"In This experiment, the investigators would like to design a new itch model based on the spatial summation of pruritic stimuli. The hypothesis behind this study (spatial summation) is that two simultaneous applications of pruritogens will result in higher itch sensation compared with a single application of pruritogen.",[504,505],"2024-05-03",{"date":578,"type":41},"2024-05-06",{"date":580,"type":41},"2024-04-01",{"date":121,"type":24},{"name":47,"class":48},""]